Call it IRP: New California Effort to Engage Stem Cell Research with Industry
Norvo, Bayer, Resilence, ElevateBio involved
California’s $12 billion stem cell and gene therapy program this morning announced a new effort to accelerate research toward the creation of “transformative regenerative medicine therapies for rare and prevalent diseases.”
Dubbed the Industry Resource Partners (IRP), the program is aimed at creating a “force-multiplier effect” by engaging industry partn…
Keep reading with a 7-day free trial
Subscribe to The California Stem Cell Report to keep reading this post and get 7 days of free access to the full post archives.